Communique from extra general meeting in Senzime AB (publ)

The extra general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 2 July 2020 in Uppsala by postal voting in advance whereby the shareholders primarily resolved on the following matters.

Introduction of employee stock option program 2020/2023

The extra general meeting resolved, in accordance with the proposal of the board of directors, to introduce employee stock option program 2020/2023 through a directed issue of warrants to the Company’s wholly owned subsidiary MD Biomedical AB, corp.reg.no 556837-0273 (the ”Subsidiary”), in order to ensure the Company’s delivery of shares according to the employee stock option program and to cover cash flow effects from potential social security costs arising from the employee stock option program and to approve transfer of warrants or shares in the Company from the Subsidiary to the participant in the employee stock option program.

The program shall include not more than 100 000 employee stock options which shall be assigned to the program participant, Anders Selin free of charge. The participant may exercise allotted and vested employee stock options during the period from 1 July 2023 to 30 September 2023. Each employee stock option shall entitle the holder to, during the exercising period and when the goals have been achieved as set out in section 7 in the proposal, acquire one (1) new share in the Company at an exercise price corresponding to 125 percent of the volume-weighted average price of the Company’s share according to Nasdaq First North Growth Market’s price list during the period of 20 trading days from 2 July 2020. If all warrants are exercised for subscription of shares, the Company’s registered share capital will increase by approximately SEK 12 500. The maximum dilutive effect as a result of the employee stock option program in 2020/2023 is calculated to not exceed 0.2 percent of the shares and votes in the Company.

Introduction of employee stock option program 2020/2024

The extra general meeting resolved, in accordance with the proposal of the board of directors, to introduce employee stock option program 2020/2024 through a directed issue of warrants to Subsidiary, in order to ensure the Company’s delivery of shares according to the employee stock option program and to cover cash flow effects from potential social security costs arising from the employee stock option program and to approve transfer of warrants or shares in the Company from the Subsidiary to the participants in the employee stock option program.

The program shall include not more than 1 100 000 employee stock options which shall be assigned to the program participants free of charge. The participant may exercise allotted and vested employee stock options during the period from 1 February 2024 to 30 April 2024. Each employee stock option shall entitle the holder to, during the exercising period and when the goals have been achieved as set out in section 9 in the proposal, acquire one (1) new share in the Company at an exercise price corresponding to 125 percent of the volume-weighted average price of the Company’s share according to Nasdaq First North Growth Market’s price list during the period of 20 trading days from 2 July 2020 (unless the participant has been employed after 31 December 2020 whereby another calculation of the exercise price shall apply as set out in section 11 in the proposal). If all warrants are exercised for subscription of shares, the Company’s registered share capital will increase by approximately SEK 43 750. The maximum dilutive effect as a result of the employee stock option program in 2020/2024 is calculated to not exceed 1.9 percent of the shares and votes in the Company.

All resolutions at the annual general meeting were adopted unanimously.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 708-13 34 17, e-mail: pia.renaudin@senzime.com

————————————

Senzime AB (publ)

The board of directors

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com